RU2014128387A - Ингибиторы рi3к для лечения фиброзных заболеваний - Google Patents

Ингибиторы рi3к для лечения фиброзных заболеваний Download PDF

Info

Publication number
RU2014128387A
RU2014128387A RU2014128387A RU2014128387A RU2014128387A RU 2014128387 A RU2014128387 A RU 2014128387A RU 2014128387 A RU2014128387 A RU 2014128387A RU 2014128387 A RU2014128387 A RU 2014128387A RU 2014128387 A RU2014128387 A RU 2014128387A
Authority
RU
Russia
Prior art keywords
pyridazinyl
compound
fibrotic disease
treatment
methyloxy
Prior art date
Application number
RU2014128387A
Other languages
English (en)
Russian (ru)
Inventor
Ричард Фрэнсис ВУСТЕР
Полин Тереса ЛАКИ
Патрик Джон Томпсон ВАЛАНС
Original Assignee
ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед filed Critical ГлаксоСмитКлайн Интеллекчуал Проперти (N 2) Лимитед
Publication of RU2014128387A publication Critical patent/RU2014128387A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2014128387A 2012-02-06 2013-02-04 Ингибиторы рi3к для лечения фиброзных заболеваний RU2014128387A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261595293P 2012-02-06 2012-02-06
US61/595,293 2012-02-06
US201261702854P 2012-09-19 2012-09-19
US61/702,854 2012-09-19
PCT/EP2013/052112 WO2013117503A2 (en) 2012-02-06 2013-02-04 Novel use

Publications (1)

Publication Number Publication Date
RU2014128387A true RU2014128387A (ru) 2016-03-27

Family

ID=47633093

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014128387A RU2014128387A (ru) 2012-02-06 2013-02-04 Ингибиторы рi3к для лечения фиброзных заболеваний

Country Status (10)

Country Link
US (2) US20150051215A1 (enExample)
EP (1) EP2812002A2 (enExample)
JP (1) JP2015509483A (enExample)
KR (1) KR20140127307A (enExample)
CN (1) CN104093408A (enExample)
AU (1) AU2013218148A1 (enExample)
BR (1) BR112014018106A2 (enExample)
CA (1) CA2861521A1 (enExample)
RU (1) RU2014128387A (enExample)
WO (1) WO2013117503A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
SG11201808478RA (en) * 2015-07-30 2018-10-30 Univ Monash Fibrotic treatment
JP6419097B2 (ja) * 2016-01-14 2018-11-07 学校法人東京農業大学 ヤマノイモ属植物からのディオスコリンの製造方法
WO2018177301A1 (zh) 2017-04-01 2018-10-04 郑州大学 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa

Also Published As

Publication number Publication date
US20160067247A1 (en) 2016-03-10
EP2812002A2 (en) 2014-12-17
CA2861521A1 (en) 2013-08-15
WO2013117503A2 (en) 2013-08-15
BR112014018106A2 (pt) 2017-06-27
WO2013117503A3 (en) 2013-10-03
KR20140127307A (ko) 2014-11-03
CN104093408A (zh) 2014-10-08
US20150051215A1 (en) 2015-02-19
AU2013218148A1 (en) 2014-07-24
JP2015509483A (ja) 2015-03-30

Similar Documents

Publication Publication Date Title
RU2013121788A (ru) Ингибиторы репликации вич
RU2014128387A (ru) Ингибиторы рi3к для лечения фиброзных заболеваний
RU2017114346A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2013542247A5 (enExample)
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
JP2014511891A5 (enExample)
JP2016506935A5 (enExample)
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
JP2014511892A5 (enExample)
JP2010525056A5 (enExample)
RU2018106453A (ru) Соединения
JP2014530900A5 (enExample)
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
RU2015149527A (ru) Производные доластатина 10 и ауристатинов
RU2016134751A (ru) Соединения
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2017105353A (ru) Соединения
JP2019501130A5 (enExample)
JP2017505293A5 (enExample)
RU2019100037A (ru) Способ лечения рассеянного склероза с использованием ингибитора lsd1
RU2016150537A (ru) Новые соединения
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
JP2015516419A5 (enExample)